MBX (MBX Biosciences) Institutional Ownership : 98.56% (As of Apr. 10, 2025)

View and export this data going back to 2024. Start your Free Trial

What is MBX Biosciences Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, MBX Biosciences's institutional ownership is 98.56%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, MBX Biosciences's Insider Ownership is 1.80%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, MBX Biosciences's Float Percentage Of Total Shares Outstanding is 0.00%.

MBX Biosciences Institutional Ownership Historical Data

The historical data trend for MBX Biosciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MBX Biosciences Institutional Ownership Chart

MBX Biosciences Historical Data

The historical data trend for MBX Biosciences can be seen below:

	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-02-28	2025-03-31
Institutional Ownership	7.24	7.22	7.01	12.21	12.35	12.54	12.51

MBX Biosciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

MBX Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MBX Biosciences Inc (NAS:MBX) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032

Website

https://www.mbxbio.com

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.